In:
Blood, American Society of Hematology, Vol. 130, No. 24 ( 2017-12-14), p. 2682-2688
Abstract:
HSCT represents an effective and definitive treatment of DADA2. HSCT can cure the immunological, hematological, and vascular phenotype of DADA2 with 100% survival at median follow-up of 18 months.
Type of Medium:
Online Resource
ISSN:
0006-4971
,
1528-0020
DOI:
10.1182/blood-2017-07-798660
Language:
English
Publisher:
American Society of Hematology
Publication Date:
2017
detail.hit.zdb_id:
1468538-3
detail.hit.zdb_id:
80069-7